Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Rochester, NY
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Asheville, NC
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Asheville, NC
Click here to add this to my saved trials
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Charlotte, NC
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Kingston, PA
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Kingston, PA
Click here to add this to my saved trials
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Florence, SC
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Florence, SC
Click here to add this to my saved trials
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
West Columbia, SC
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
West Columbia, SC
Click here to add this to my saved trials
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Rapid City, SD
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Rapid City, SD
Click here to add this to my saved trials
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Germantown, TN
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Germantown, TN
Click here to add this to my saved trials
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Abilene, TX
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Abilene, TX
Click here to add this to my saved trials
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Austin, TX
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fort Worth, TX
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Harlingen, TX
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Harlingen, TX
Click here to add this to my saved trials
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
The Woodlands, TX
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
The Woodlands, TX
Click here to add this to my saved trials
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Willow Park, TX
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Willow Park, TX
Click here to add this to my saved trials
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bellevue, WA
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bellevue, WA
Click here to add this to my saved trials
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Shawnee Mission, KA
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Shawnee Mission, KA
Click here to add this to my saved trials
Safety and Efficacy of TrueTear™ for the Treatment of Meibomian Gland Disease
Prospective, Open-Label, Randomized, Proof of Concept Study Exploring Application of TrueTear™ for the Treatment of Meibomian Gland Disease
Status: Enrolling
Updated:  12/31/1969
Andover Eye Associates
mi
from
Andover, MA
Safety and Efficacy of TrueTear™ for the Treatment of Meibomian Gland Disease
Prospective, Open-Label, Randomized, Proof of Concept Study Exploring Application of TrueTear™ for the Treatment of Meibomian Gland Disease
Status: Enrolling
Updated: 12/31/1969
Andover Eye Associates
mi
from
Andover, MA
Click here to add this to my saved trials
Clinical Characterization of Symptomatic Populations
Clinical Characterization of Symptomatic Populations
Status: Enrolling
Updated:  12/31/1969
VRC East
mi
from
Jacksonville, FL
Clinical Characterization of Symptomatic Populations
Clinical Characterization of Symptomatic Populations
Status: Enrolling
Updated: 12/31/1969
VRC East
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Clinical Characterization of Symptomatic Populations
Clinical Characterization of Symptomatic Populations
Status: Enrolling
Updated:  12/31/1969
University of Waterloo Center for Contact Lens Research
mi
from
Waterloo,
Clinical Characterization of Symptomatic Populations
Clinical Characterization of Symptomatic Populations
Status: Enrolling
Updated: 12/31/1969
University of Waterloo Center for Contact Lens Research
mi
from
Waterloo,
Click here to add this to my saved trials
Effects of EED on Zn Absorption and Retention in Children From a Standard Dose
Effects of Environmental Enteric Dysfunction (EED) on Zinc (Zn) Absorption and Retention in Young Children: Study 1 - Absorption of Zn and Vitamin A From a Standard Dose
Status: Enrolling
Updated:  12/31/1969
University of Colorado Denver, School of Medicine
mi
from
Aurora, CO
Effects of EED on Zn Absorption and Retention in Children From a Standard Dose
Effects of Environmental Enteric Dysfunction (EED) on Zinc (Zn) Absorption and Retention in Young Children: Study 1 - Absorption of Zn and Vitamin A From a Standard Dose
Status: Enrolling
Updated: 12/31/1969
University of Colorado Denver, School of Medicine
mi
from
Aurora, CO
Click here to add this to my saved trials
Effects of EED on Zn Absorption and Retention in Children From a Standard Dose
Effects of Environmental Enteric Dysfunction (EED) on Zinc (Zn) Absorption and Retention in Young Children: Study 1 - Absorption of Zn and Vitamin A From a Standard Dose
Status: Enrolling
Updated:  12/31/1969
icddr,b (International Centre for Diarrheal Disease Research, Bangladesh
mi
from
Dhaka,
Effects of EED on Zn Absorption and Retention in Children From a Standard Dose
Effects of Environmental Enteric Dysfunction (EED) on Zinc (Zn) Absorption and Retention in Young Children: Study 1 - Absorption of Zn and Vitamin A From a Standard Dose
Status: Enrolling
Updated: 12/31/1969
icddr,b (International Centre for Diarrheal Disease Research, Bangladesh
mi
from
Dhaka,
Click here to add this to my saved trials
Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study
Changes in Peripapillary Blood Flow After Use of Anti-glaucoma Medications: A Prospective, Quantitative OCT Angiography Study
Status: Enrolling
Updated:  12/31/1969
Glaucoma Research Center - Wills Eye Hospital
mi
from
Philadelphia, PA
Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study
Changes in Peripapillary Blood Flow After Use of Anti-glaucoma Medications: A Prospective, Quantitative OCT Angiography Study
Status: Enrolling
Updated: 12/31/1969
Glaucoma Research Center - Wills Eye Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Non-dispensing Study to Check Prescription Equivalence of Two Daily Disposable Toric Contact Lens Types
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Jacksonville, FL
Non-dispensing Study to Check Prescription Equivalence of Two Daily Disposable Toric Contact Lens Types
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Non-dispensing Study to Check Prescription Equivalence of Two Daily Disposable Toric Contact Lens Types
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New York, NY
Non-dispensing Study to Check Prescription Equivalence of Two Daily Disposable Toric Contact Lens Types
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2b/3, Multicenter, Randomized, Double-masked, Vehicle-controlled Clinical Study to Assess the Efficacy and Safety of Topical CyclASol® for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (ESSENCE Trial)
Status: Enrolling
Updated:  12/31/1969
CYS-003 Investigational Site
mi
from
Memphis, TN
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2b/3, Multicenter, Randomized, Double-masked, Vehicle-controlled Clinical Study to Assess the Efficacy and Safety of Topical CyclASol® for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (ESSENCE Trial)
Status: Enrolling
Updated: 12/31/1969
CYS-003 Investigational Site
mi
from
Memphis, TN
Click here to add this to my saved trials
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2b/3, Multicenter, Randomized, Double-masked, Vehicle-controlled Clinical Study to Assess the Efficacy and Safety of Topical CyclASol® for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (ESSENCE Trial)
Status: Enrolling
Updated:  12/31/1969
CYS-003 Investigational Site
mi
from
Newport Beach, CA
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2b/3, Multicenter, Randomized, Double-masked, Vehicle-controlled Clinical Study to Assess the Efficacy and Safety of Topical CyclASol® for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (ESSENCE Trial)
Status: Enrolling
Updated: 12/31/1969
CYS-003 Investigational Site
mi
from
Newport Beach, CA
Click here to add this to my saved trials
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2b/3, Multicenter, Randomized, Double-masked, Vehicle-controlled Clinical Study to Assess the Efficacy and Safety of Topical CyclASol® for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (ESSENCE Trial)
Status: Enrolling
Updated:  12/31/1969
CYS-003 Investigational Site
mi
from
Torrance, CA
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2b/3, Multicenter, Randomized, Double-masked, Vehicle-controlled Clinical Study to Assess the Efficacy and Safety of Topical CyclASol® for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (ESSENCE Trial)
Status: Enrolling
Updated: 12/31/1969
CYS-003 Investigational Site
mi
from
Torrance, CA
Click here to add this to my saved trials
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2b/3, Multicenter, Randomized, Double-masked, Vehicle-controlled Clinical Study to Assess the Efficacy and Safety of Topical CyclASol® for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (ESSENCE Trial)
Status: Enrolling
Updated:  12/31/1969
CYS-003 Investigational Site
mi
from
Louisville, KY
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2b/3, Multicenter, Randomized, Double-masked, Vehicle-controlled Clinical Study to Assess the Efficacy and Safety of Topical CyclASol® for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (ESSENCE Trial)
Status: Enrolling
Updated: 12/31/1969
CYS-003 Investigational Site
mi
from
Louisville, KY
Click here to add this to my saved trials
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2b/3, Multicenter, Randomized, Double-masked, Vehicle-controlled Clinical Study to Assess the Efficacy and Safety of Topical CyclASol® for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (ESSENCE Trial)
Status: Enrolling
Updated:  12/31/1969
CYS-003 Investigational Site
mi
from
Andover, MA
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2b/3, Multicenter, Randomized, Double-masked, Vehicle-controlled Clinical Study to Assess the Efficacy and Safety of Topical CyclASol® for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (ESSENCE Trial)
Status: Enrolling
Updated: 12/31/1969
CYS-003 Investigational Site
mi
from
Andover, MA
Click here to add this to my saved trials
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2b/3, Multicenter, Randomized, Double-masked, Vehicle-controlled Clinical Study to Assess the Efficacy and Safety of Topical CyclASol® for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (ESSENCE Trial)
Status: Enrolling
Updated:  12/31/1969
CYS-003 Investigational Site
mi
from
Indianapolis, IN
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2b/3, Multicenter, Randomized, Double-masked, Vehicle-controlled Clinical Study to Assess the Efficacy and Safety of Topical CyclASol® for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (ESSENCE Trial)
Status: Enrolling
Updated: 12/31/1969
CYS-003 Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2b/3, Multicenter, Randomized, Double-masked, Vehicle-controlled Clinical Study to Assess the Efficacy and Safety of Topical CyclASol® for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (ESSENCE Trial)
Status: Enrolling
Updated:  12/31/1969
CYS-003 Investigational Site
mi
from
Raynham, MA
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2b/3, Multicenter, Randomized, Double-masked, Vehicle-controlled Clinical Study to Assess the Efficacy and Safety of Topical CyclASol® for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (ESSENCE Trial)
Status: Enrolling
Updated: 12/31/1969
CYS-003 Investigational Site
mi
from
Raynham, MA
Click here to add this to my saved trials
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2b/3, Multicenter, Randomized, Double-masked, Vehicle-controlled Clinical Study to Assess the Efficacy and Safety of Topical CyclASol® for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (ESSENCE Trial)
Status: Enrolling
Updated:  12/31/1969
CYS-003 Investigational Site
mi
from
Nashville, TN
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2b/3, Multicenter, Randomized, Double-masked, Vehicle-controlled Clinical Study to Assess the Efficacy and Safety of Topical CyclASol® for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (ESSENCE Trial)
Status: Enrolling
Updated: 12/31/1969
CYS-003 Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2b/3, Multicenter, Randomized, Double-masked, Vehicle-controlled Clinical Study to Assess the Efficacy and Safety of Topical CyclASol® for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (ESSENCE Trial)
Status: Enrolling
Updated:  12/31/1969
CYS-003 Investigational Site
mi
from
Norfolk, VA
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2b/3, Multicenter, Randomized, Double-masked, Vehicle-controlled Clinical Study to Assess the Efficacy and Safety of Topical CyclASol® for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (ESSENCE Trial)
Status: Enrolling
Updated: 12/31/1969
CYS-003 Investigational Site
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study Raindrop Near Vision Inlay in Presbyopes Implanted in Corneal Pockets
A Prospective Study to Evaluate the Raindrop Near Vision Inlay in Presbyopes Implanted in Corneal Pockets With a Delayed or Non-Delayed Approach
Status: Enrolling
Updated:  12/31/1969
The Eye Center of North Florida
mi
from
Panama City, FL
A Study Raindrop Near Vision Inlay in Presbyopes Implanted in Corneal Pockets
A Prospective Study to Evaluate the Raindrop Near Vision Inlay in Presbyopes Implanted in Corneal Pockets With a Delayed or Non-Delayed Approach
Status: Enrolling
Updated: 12/31/1969
The Eye Center of North Florida
mi
from
Panama City, FL
Click here to add this to my saved trials
A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia
A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia
Status: Enrolling
Updated:  12/31/1969
Andover Eye Associates
mi
from
Andover, MA
A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia
A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia
Status: Enrolling
Updated: 12/31/1969
Andover Eye Associates
mi
from
Andover, MA
Click here to add this to my saved trials
Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis
Prospective Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis Who Are Not Well Controlled With, or Intolerant of, Topical or Systemic Corticosteroids
Status: Enrolling
Updated:  12/31/1969
Washington University in St. Louis
mi
from
Saint Louis, MO
Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis
Prospective Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis Who Are Not Well Controlled With, or Intolerant of, Topical or Systemic Corticosteroids
Status: Enrolling
Updated: 12/31/1969
Washington University in St. Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Inflammasomes in Cell Death in FTMH, ERM, and RRD
Inflammasomes in Cell Death in Macular Hole, Epiretinal Membrane, and Rhegmatogenous Retinal Detachment
Status: Enrolling
Updated:  12/31/1969
MidAtlantic Retina-Wills Eye Hospital
mi
from
Philadelphia, PA
Inflammasomes in Cell Death in FTMH, ERM, and RRD
Inflammasomes in Cell Death in Macular Hole, Epiretinal Membrane, and Rhegmatogenous Retinal Detachment
Status: Enrolling
Updated: 12/31/1969
MidAtlantic Retina-Wills Eye Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients
The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients, Pressure Control and Pupil Effects
Status: Enrolling
Updated:  12/31/1969
Wake Forest Baptist Health Eye Center
mi
from
Winston-Salem, NC
The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients
The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients, Pressure Control and Pupil Effects
Status: Enrolling
Updated: 12/31/1969
Wake Forest Baptist Health Eye Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Lotoprednol vs. Prednisolone and Fluorometholone
Efficacy and Safety of Loteprednol 0.5% Gel for Routine Prophylaxis After Photorefractive Keratectomy Compared to Prednisolone Acetate 1% Suspension and Fluorometholone 0.1% Suspension
Status: Enrolling
Updated:  12/31/1969
Moran Eye Center - Midvalley Location
mi
from
Murray, UT
Lotoprednol vs. Prednisolone and Fluorometholone
Efficacy and Safety of Loteprednol 0.5% Gel for Routine Prophylaxis After Photorefractive Keratectomy Compared to Prednisolone Acetate 1% Suspension and Fluorometholone 0.1% Suspension
Status: Enrolling
Updated: 12/31/1969
Moran Eye Center - Midvalley Location
mi
from
Murray, UT
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigative Site
mi
from
Phoenix, AZ
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigative Site
mi
from
Winter Haven, FL
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigative Site
mi
from
Winter Haven, FL
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Asheville, NC
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Asheville, NC
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Austin, TX
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigative Site
mi
from
Beverly Hills, CA
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigative Site
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Encino, CA
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Encino, CA
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Redlands, CA
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Redlands, CA
Click here to add this to my saved trials